

# Identification of deamidated peptides in cytokine-exposed MIN6 cells through LC-MS/MS using a shortened digestion time and inspection of MS2 spectra

*Aisha Callebaut<sup>1</sup>, Rita Derua<sup>2,3</sup>, Saurabh Vig<sup>1</sup>, Thomas Delong<sup>4</sup>, Chantal Mathieu<sup>1</sup>*

*and Lut Overbergh<sup>1,\*</sup>*

<sup>1</sup>Laboratory for Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium. <sup>2</sup>Laboratory of Protein Phosphorylation and Proteomics, KU Leuven, Leuven, Belgium. <sup>3</sup>SyBioMa, KU Leuven, Leuven, Belgium. <sup>4</sup>Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz, Aurora, CO, USA.

\* Email: [lutgart.overbergh@kuleuven.be](mailto:lutgart.overbergh@kuleuven.be)

Figure S1: Unique proteins and average protein coverage under various digestion conditions.

Table S1: Amount and fraction of total unique peptides of identified Asn and Gln deamidations under various digestion conditions (excel).


Table S2: Amount and fraction of total unique peptides of identified in vitro and in vivo Asn and Gln deamidations (excel).

Table S3: Confirmed Gln deamidations in control and cytokine-exposed MIN6 cells (excel).


Table S4: Confirmed Asn deamidations in control and cytokine-exposed MIN6 cells (excel).


Table S5: Summary table of properties of confirmed Asn and Gln deamidations in control and cytokine-exposed MIN6 cells (excel).

Figure S2: MS2 spectra of peptides with increased deamidation upon cytokine-exposure.



**Supplementary Figure 1.** Unique proteins and average protein coverage under various digestion conditions. Total number of proteins identified (**A**) and average protein coverage of identified proteins (**B**) after digestion at different pH's (8, 6 and 5) and during different times (overnight (ON), 90 min and 30'). Results are shown as mean  $\pm$  SD, n=3 independent experiments. One-way ANOVA with Dunnett's correction for multiple comparisons, \*p<0.05.







hnRNPH N38 (I), hnRNPU N57 (J), PDI N109 (K) and N451 (L) , PDIA3 N199 (M) and N474 (N-O) and Secretogranin-1 Q594 (P).